MAPT and amyloidosis: A multicenter study compared the brain distribution and retention of [18F]Flortaucipir to florbetapir PET, also considering the amyloid status, type of diagnosis, age and cognitive function, and supported the hypothesis that the Aβ and Tau pathology may start independently [33].